Peripheral Vascular Diseases
📧 Sign up to get email alerts when something new happens for Peripheral Vascular Diseases.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-18EMA Authorised: Brilique (ticagrelor) — AstraZeneca AB
Brilique (ticagrelor) has been authorised for use in the European Union for indications related to Acute Coronary Syndrome and peripheral va…
-
EMA approval · 2026-02-05EMA Authorised: Clopidogrel Zentiva (previously Clopidogrel Winthrop) (clopidogrel) — Zentiva k.s.
The European Medicines Agency authorised Zentiva’s generic clopidogrel product for prevention of stroke, myocardial infarction, acute corona…
-
EMA approval · 2024-02-29EMA Authorised: Clopidogrel Teva (hydrogen sulphate) (clopidogrel (as hydrogen sulfate)) — Teva Pharma B.V.
EMA authorised Clopidogrel Teva (hydrogen sulphate) for multiple cardiovascular indications including acute coronary syndrome, myocardial in…
-
EMA approval · 2023-12-19EMA Authorised: Clopidogrel Taw Pharma (previously Clopidogrel Mylan) (clopidogrel hydrochloride) — Taw Pharma (Ireland) Limited
EMA authorised a clopidogrel product (clopidogrel hydrochloride) by Taw Pharma (Ireland) Limited for peripheral vascular diseases, stroke, m…
-
EMA approval · 2020-03-11EMA Authorised: Clopidogrel BGR (previously Zylagren) (clopidogrel (as hydrogen sulfate)) — Biogaran
European Medicines Agency authorised Clopidogrel BGR (clopidogrel as hydrogen sulfate) by Biogaran for peripheral vascular diseases, stroke,…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2018-08-01EMA Authorised: Clopidogrel HCS (clopidogrel (as hydrochloride)) — HCS bvba
The EMA authorised Clopidogrel HCS (clopidogrel hydrochloride) for several cardiovascular indications including peripheral vascular diseases…